Effects of sparsentan: A Synthesis of Findings from 7 Studies

  1. Home
  2. Effects of sparsentan
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of sparsentan: A Synthesis of Findings from 7 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of sparsentan: A Synthesis of Findings from 7 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Sparsentan is a novel drug that may help reduce proteinuria in patients with IgA nephropathy. 2 found that patients treated with sparsentan had significantly lower proteinuria compared to those who received irbesartan. This effect was maintained after 36 weeks of treatment. In the long-term results of the PROTECT trial, 7 , sparsentan showed sustained proteinuria reduction and improvement in kidney function for 2 years compared to irbesartan.

Sparsentan could play a significant role in treating kidney disease. 5 indicates that sparsentan, being an endothelin receptor antagonist, has the potential to improve kidney blood flow and reduce proteinuria.

Furthermore, research in 6 showed that sparsentan may inhibit sodium and potassium ion channels in kidney cells. This action could contribute to the proteinuria-reducing effect of sparsentan.

Benefits and Risks

Benefit Summary

Sparsentan is a promising new drug that may significantly reduce proteinuria in patients with IgA nephropathy. Studies from 2 and 7 suggest that sparsentan can lead to long-term maintenance of proteinuria reduction and improved kidney function. Additionally, sparsentan is expected to improve kidney blood flow and prevent kidney damage. 5

Risk Summary

The safety of sparsentan is considered comparable to irbesartan. 2 and 7 did not report any instances of severe edema, heart failure, hepatotoxicity, or edema-related discontinuations in patients treated with sparsentan. However, as with any medication, sparsentan can potentially cause side effects. It is crucial to consult with your doctor before using sparsentan and thoroughly discuss the risks and benefits.

Comparison of Studies

Similarities of Studies

All these studies indicate that sparsentan is a promising treatment option for patients with IgA nephropathy, showing the potential to reduce proteinuria. These studies were conducted to evaluate the safety and efficacy of sparsentan.

Differences of Studies

These studies employed different methodologies. For instance, the PROTECT trials from 2 and 7 were double-blind, placebo-controlled trials, while the research in 6 evaluated the actions of sparsentan at the cellular level. These studies targeted distinct patient populations. For example, the PROTECT trials ( 2 and 7 ) focused on patients with IgA nephropathy, while the study in 4 targeted those with FSGS. Furthermore, the studies had different durations. The PROTECT trials ( 2 and 7 ) spanned two years, whereas the research in 6 was shorter.

Consistency and Discrepancies of Results

These studies suggest that sparsentan is a potentially beneficial treatment for reducing proteinuria in IgA nephropathy patients. However, these studies do not provide sufficient information about the long-term effects of sparsentan or its effects on other kidney diseases.

Practical Applications and Considerations

Sparsentan is a new medication that may help reduce proteinuria in individuals with IgA nephropathy. However, it is crucial to understand that sparsentan might not be effective for all patients, and it can potentially cause side effects. Consulting with your doctor before using sparsentan and carefully considering the risks and benefits is vital.

Limitations of Current Research

These studies do not provide enough information about the long-term effects of sparsentan or its effects on other kidney diseases. Additionally, generalizing the results requires caution because these studies involved distinct patient populations.

Directions for Future Research

Future research needs to further investigate the long-term effects of sparsentan, its impact on other kidney diseases, and its safety. Studies should also explore ways to enhance the efficacy of sparsentan and minimize side effects.

Conclusion

Sparsentan shows promise as a new treatment for reducing proteinuria in patients with IgA nephropathy. Sparsentan could play a vital role in the treatment of kidney disease. However, it's essential to recognize that sparsentan might not be effective for everyone, and it can potentially lead to side effects. Consultation with your doctor before using sparsentan and careful consideration of the risks and benefits are crucial. Further research is necessary to explore the long-term effects of sparsentan, its impact on other kidney diseases, and its safety.

Literature analysis of 7 papers
Positive Content
7
Neutral Content
0
Negative Content
0
Article Type
3
0
0
1
7
1.

Lack of pharmacodynamic interaction of silodosin, a highly selective alpha1a-adrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men.

Author: MacDiarmidScott A, HillLawrence A, VolinnWeining, HoelGary

Safe coadministration
Mild adverse events

Co-administration of silodosin with sildenafil or tadalafil did not cause clinically significant orthostatic changes in blood pressure or heart rate in healthy men. The study found no significant differences in orthostatic effects between the treatments.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

2.

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.

Author: HeerspinkHiddo J L, RadhakrishnanJai, AlpersCharles E, BarrattJonathan, BielerStewart, DivaUlysses, InrigJula, KomersRadko, MercerAlex, NoronhaIrene L, RheaultMichelle N, RoteWilliam, RovinBrad, TrachtmanHoward, TrimarchiHernán, WongMuh Geot, PerkovicVlado,

Proteinuria reduction

This interim analysis of the PROTECT trial found that once-daily treatment with sparsentan produced a meaningful reduction in proteinuria compared with irbesartan in adults with IgA nephropathy. The safety of sparsentan was similar to irbesartan.

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.

Author: RovinBrad H, BarrattJonathan, HeerspinkHiddo J L, AlpersCharles E, BielerStewart, ChaeDong-Wan, DivaUlysses A, FloegeJürgen, GesualdoLoreto, InrigJula K, KohanDonald E, KomersRadko, KooiengaLaura Ann, LafayetteRichard, MaesBart, MałeckiRobert, MercerAlex, NoronhaIrene L, OhSe Won, PehChen Au, PragaManuel, PreciadoPriscila, RadhakrishnanJai, RheaultMichelle N, RoteWilliam E, TangSydney C W, TesarVladimir, TrachtmanHoward, TrimarchiHernán, TumlinJames A, WongMuh Geot, PerkovicVlado,

Improved kidney function
Reduced proteinuria

This report provides the final analysis of the PROTECT trial, showing that sparsentan, a dual endothelin angiotensin receptor antagonist, continued to significantly reduce proteinuria compared to irbesartan in patients with immunoglobulin A nephropathy over 110 weeks.

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.